HIGHLIGHTS   |  December 20, 2019   FDA Approves Abbreviated New Drug Applications for Everolimus Generic Drug The FDA approved the first generic for everolimus (Afinitor) for multiple indications. Read more   SP-2577 Granted Fast Track Designation by the FDA for Patients with Ewing Sarcoma SP-2577 (Seclidemstat) has been granted fast track designation by the FDA for the treatment of patients with Ewing sarcoma who have relapsed or are refractory to standard-of-care therapy. Read more   ICYMI: Phase III ALTA-1L Trial Shows Promise for Patients with Non-Small Cell Lung Cancer The ongoing phase III ALTA-1L trial of brigatinib versus crizotinib suggested that brigatinib reduced the risk of disease progression or death in adults with advanced ALK-positive NSCLC who had not received a prior ALK inhibitor. Read more

ADVERTISEMENT Proven portfolio of tests + services, that’s our Foundation. Our portfolio of genomic tests & services is designed for cancer patients at any line of therapy, with proven utility for clinical decision making. Rx only; advanced cancer; doesn’t guarantee treatment match. Learn more